NASDAQ:TLSI TriSalus Life Sciences (TLSI) Stock Price, News & Analysis $4.77 +0.11 (+2.36%) Closing price 09/14/2026 04:00 PM EasternExtended Trading$4.78 +0.01 (+0.10%) As of 09/14/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About TriSalus Life Sciences Stock (NASDAQ:TLSI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get TriSalus Life Sciences alerts:Sign Up Key Stats Today's Range$4.58▼$4.8450-Day Range$3.68▼$5.7452-Week Range$2.20▼$7.95Volume101,306 shsAverage Volume102,676 shsMarket Capitalization$293.74 millionP/E RatioN/ADividend YieldN/APrice Target$8.67Consensus RatingHold Company Overview TriSalus Life Sciences is an oncology company focused on developing technologies and therapies for patients with liver and pancreatic tumors. The company’s approach combines investigational immunotherapies with drug-delivery technologies intended to improve treatment access to solid tumors, which can be difficult to reach through conventional systemic administration. TriSalus is best known for its Pressure-Enabled Drug Delivery (PEDD) platform, which is designed to deliver medicines directly into tumors or their surrounding blood vessels by using controlled pressure. The company also develops related infusion systems and procedures for regional delivery, including the TriSalus SmartFlow system, an FDA-cleared device used in certain hepatic artery infusion procedures. In addition to its device and delivery platforms, TriSalus is advancing an oncology pipeline that includes nelitolimod, an investigational immunotherapy designed to stimulate immune activity through the toll-like receptor 9 pathway. The company’s clinical development efforts have primarily focused on liver and pancreatic cancers, with research and commercial activities centered in the United States.AI Generated. May Contain Errors. Read More TriSalus Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreTLSI MarketRank™: TriSalus Life Sciences scored higher than 47% of companies evaluated by MarketBeat, and ranked 584th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingTriSalus Life Sciences has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialTriSalus Life Sciences has a consensus price target of $8.67, representing about 81.7% upside from its current price of $4.77.Amount of Analyst CoverageTriSalus Life Sciences has only been the subject of 3 research reports in the past 90 days.Read more about TriSalus Life Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for TriSalus Life Sciences are expected to grow in the coming year, from ($0.31) to ($0.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TriSalus Life Sciences is -3.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TriSalus Life Sciences is -3.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about TriSalus Life Sciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.16% of the float of TriSalus Life Sciences has been sold short.Short Interest Ratio / Days to CoverTriSalus Life Sciences has a short interest ratio ("days to cover") of 35.88, which indicates bearish sentiment.Change versus previous monthShort interest in TriSalus Life Sciences has recently decreased by 2.59%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTriSalus Life Sciences does not currently pay a dividend.Dividend GrowthTriSalus Life Sciences does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment1.00 News SentimentTriSalus Life Sciences has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 23 news articles for TriSalus Life Sciences this week, compared to 3 articles on an average week. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, TriSalus Life Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders16.30% of the stock of TriSalus Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions2.58% of the stock of TriSalus Life Sciences is held by institutions.Read more about TriSalus Life Sciences' insider trading history. Receive TLSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TriSalus Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TLSI Stock News HeadlinesTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Average Recommendation of "Hold" from BrokeragesSeptember 14 at 3:14 AM | americanbankingnews.comEquities Analysts Offer Predictions for TLSI Q3 EarningsSeptember 13 at 1:13 AM | americanbankingnews.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required. | Stansberry Research (Ad)TriSalus Life Sciences (NASDAQ:TLSI) Research Coverage Started at HC WainwrightSeptember 12 at 2:37 AM | americanbankingnews.comHC Wainwright & Co. initiates coverage of TriSalus Life Sciences with a buy ratingSeptember 9, 2026 | msn.comTriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment ConferenceAugust 31, 2026 | markets.ft.comTriSalus Life Sciences, Inc. (TLSI) Q2 2026 Earnings Call TranscriptAugust 6, 2026 | seekingalpha.comTriSalus Life Sciences Reports Second Quarter 2026 ResultsAugust 6, 2026 | businesswire.comSee More Headlines TLSI Stock Analysis - Frequently Asked Questions How have TLSI shares performed this year? TriSalus Life Sciences' stock was trading at $6.98 at the beginning of the year. Since then, TLSI stock has decreased by 31.7% and is now trading at $4.77. How were TriSalus Life Sciences' earnings last quarter? TriSalus Life Sciences, Inc. (NASDAQ:TLSI) announced its quarterly earnings results on Thursday, August, 6th. The company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by $0.01. The firm earned $11.41 million during the quarter, compared to analyst estimates of $10.27 million. Read the conference call transcript. Who are TriSalus Life Sciences' major shareholders? Top institutional shareholders of TriSalus Life Sciences include First Light Asset Management LLC (10.64%), BlackRock Inc. (4.33%), Nantahala Capital Management LLC (1.62%) and Bank of America Corp DE (0.33%). Insiders that own company stock include Equity Ab Frankenius, Michael P Stansky, Mary T Szela, George Kelly Martin, Sean Murphy, Bryan F Cox, Mats Wahlstrom, Richard Marshak, Jodi Devlin, Gary B Gordon and James Emmett Young. View institutional ownership trends. How do I buy shares of TriSalus Life Sciences? Shares of TLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of TriSalus Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that TriSalus Life Sciences investors own include AutoZone (AZO), Intel (INTC), Meta Platforms (META), Merck & Co., Inc. (MRK), TJX Companies (TJX), Abacus Health Products (ABAHF) and Airbnb (ABNB). Company Calendar Last Earnings8/06/2026Today9/14/2026H.C. Wainwright 28th Annual Global Investment Conference9/14/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 TLSI's financial health is in the Green zone, according to TradeSmith. TLSI has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:TLSI Previous SymbolNASDAQ:TLSI CIK1826667 Webtrisaluslifesci.com Phone888-321-5212FaxN/AEmployees102Year Founded2009Price Target and Rating Average Price Target for TriSalus Life Sciences$8.67 High Price Target$11.00 Low Price Target$7.00 Potential Upside/Downside+81.7%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$39.23 million Net Margins-62.59% Pretax Margin-62.56% Return on EquityN/A Return on Assets-64.47% Debt Debt-to-Equity Ratio5.05 Current Ratio5.35 Quick Ratio4.97 Sales & Book Value Annual Sales$45.15 million Price / Sales6.51 Cash FlowN/A Price / Cash FlowN/A Book Value($0.68) per share Price / Book-7.01Miscellaneous Outstanding Shares61,580,000Free Float51,538,000Market Cap$293.74 million OptionableNot Optionable Beta0.44 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:TLSI) was last updated on 9/15/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TriSalus Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TriSalus Life Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
